Eli Lilly and Company (NYSE:LLY) Shares Acquired by Heritage Investors Management Corp

Heritage Investors Management Corp grew its position in Eli Lilly and Company (NYSE:LLY) by 13.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,149 shares of the company’s stock after purchasing an additional 137 shares during the period. Heritage Investors Management Corp’s holdings in Eli Lilly and Company were worth $1,018,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Lynx Investment Advisory acquired a new position in shares of Eli Lilly and Company in the second quarter valued at about $32,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter worth about $36,000. Cedar Mountain Advisors LLC boosted its stake in shares of Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after buying an additional 16 shares during the last quarter. Morton Brown Family Wealth LLC boosted its stake in shares of Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the last quarter. Finally, Unique Wealth Strategies LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter worth about $45,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $806.60 on Wednesday. The business has a 50 day simple moving average of $905.20 and a two-hundred day simple moving average of $867.96. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The stock has a market capitalization of $765.72 billion, a P/E ratio of 87.20, a PEG ratio of 3.09 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same period in the previous year, the company earned $0.10 EPS. Eli Lilly and Company’s revenue was up 20.4% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 13.23 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.64%. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on LLY. Wells Fargo & Company upped their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Guggenheim upped their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Bank of America lowered their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Berenberg Bank increased their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday. Three analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,008.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.